Pembrolizumab + Carboplatin + Cisplatin + Pemetrexed + Lenvatinib + Placebo matching lenvatinib
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Nonsquamous Non-small Cell Lung Cancer
Conditions
Nonsquamous Non-small Cell Lung Cancer
Trial Timeline
Mar 25, 2019 → Aug 30, 2024
NCT ID
NCT03829319About Pembrolizumab + Carboplatin + Cisplatin + Pemetrexed + Lenvatinib + Placebo matching lenvatinib
Pembrolizumab + Carboplatin + Cisplatin + Pemetrexed + Lenvatinib + Placebo matching lenvatinib is a phase 3 stage product being developed by Eisai for Nonsquamous Non-small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03829319. Target conditions include Nonsquamous Non-small Cell Lung Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04716933 | Phase 3 | Completed |
| NCT03829319 | Phase 3 | Completed |
Competing Products
7 competing products in Nonsquamous Non-small Cell Lung Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pemetrexed + Erlotinib + Pemetrexed + Erlotinib | Eli Lilly | Phase 2 | 52 |
| Patritumab Deruxtecan + Platinum-based chemotherapy | Daiichi Sankyo | Phase 3 | 77 |
| Pembrolizumab + Carboplatin + Cisplatin + Pemetrexed + Lenvatinib + Placebo matching lenvatinib | Eisai | Phase 3 | 77 |
| Pemetrexed | Eli Lilly | Phase 2 | 52 |
| Pembrolizumab + Pemetrexed + Carboplatin + Cisplatin + Olaparib | Merck | Phase 3 | 77 |
| Erlotinib | Roche | Pre-clinical | 23 |
| Pemetrexed + Carboplatin + demcizumab | Mereo BioPharma | Phase 2 | 44 |